A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation–associated TMA

伊库利珠单抗 医学 血栓性微血管病 内科学 临床终点 造血干细胞移植 肾功能 移植 前瞻性队列研究 胃肠病学 累积发病率 外科 免疫学 补体系统 临床试验 免疫系统 疾病
作者
Sonata Jodele,Christopher E. Dandoy,Paibel Ixia Aguayo-Hiraldo,Adam Lane,Ashley Teusink‐Cross,Anthony Sabulski,Kana Mizuno,Benjamin L. Laskin,Jason Lawrence Freedman,Stella M. Davies
出处
期刊:Blood [Elsevier BV]
卷期号:143 (12): 1112-1123 被引量:62
标识
DOI:10.1182/blood.2023022526
摘要

ABSTRACT: High-risk, complement mediated, untreated transplant-associated thrombotic microangiopathy (hrTMA) has dismal outcomes due to multi-organ dysfunction syndrome (MODS). The complement C5 blocker eculizumab shows promising results in hrTMA, but has not been prospectively studied in hematopoietic stem cell transplant (HCT) recipients. We performed the first multi-institutional prospective study in children and young adults to evaluate eculizumab as an early targeted intervention for hrTMA/MODS. We hypothesized that eculizumab would more than double survival in HCT recipients with hrTMA, compared to our prior study of prospectively screened, untreated hrTMAs serving as historical controls. HrTMA features (elevated terminal complement (sC5b-9) and proteinuria measured by random urine protein/creatinine ratio (≥1mg/mg)) were required for inclusion. The primary endpoint was survival at 6 six-months from hrTMA diagnosis. Secondary endpoints were cumulative incidence of MODS 6 months after hrTMA diagnosis and 1-year posttransplant survival. Eculizumab dosing included intensive loading, induction, and maintenance phases for up to 24 weeks of therapy. All 21 evaluated study subjects had MODS. Primary and secondary study endpoints were met by demonstrating survival of 71% (P < .0001) 6 months after hrTMA diagnosis and 62% 1 year after transplant. Of fifteen survivors, 11 (73%) fully recovered organ function and are well. Our study demonstrates significant improvement in survival and recovery of organ function in hrTMA using an intensified eculizumab dosing and real time biomarker monitoring. This study serves as a benchmark for planning future studies that should focus on preventative measures or targeted therapy to be initiated prior to organ injury. This trial was registered at www.clinicaltrials.gov as #NCT03518203.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
科研通AI65的应助被qwer采纳,获得10
1秒前
2秒前
2秒前
老实幻姬完成签到,获得积分10
2秒前
虚幻百川完成签到,获得积分0
3秒前
虚拟的水壶完成签到,获得积分10
3秒前
3秒前
momo123完成签到,获得积分10
4秒前
4秒前
123完成签到,获得积分20
4秒前
刘欣媛发布了新的文献求助10
4秒前
5秒前
hh完成签到,获得积分10
5秒前
whisper发布了新的文献求助10
5秒前
Echor完成签到,获得积分10
6秒前
6秒前
6秒前
无极微光的应助被O耶采纳,获得20
6秒前
文静的摩托完成签到,获得积分10
6秒前
终梦的应助被momo123采纳,获得10
7秒前
8秒前
虎虎完成签到,获得积分10
8秒前
8秒前
9秒前
我是老大的应助被假装有昵称采纳,获得10
9秒前
英俊的铭的应助被十二点的茶采纳,获得10
10秒前
10秒前
10秒前
10秒前
10秒前
10秒前
冷酷以山发布了新的文献求助100
11秒前
11秒前
我有颗糖完成签到,获得积分20
11秒前
星1993发布了新的文献求助10
11秒前
书包王完成签到,获得积分10
12秒前
12秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181155
求助须知:如何正确求助?哪些是违规求助? 9571140
关于积分的说明 21816740
捐赠科研通 7777528
什么是DOI,文献DOI怎么找? 3433436
关于科研通互助平台的介绍 2557664
邀请新用户注册赠送积分活动 2479482